Ghost Tree Capital’s Relmada Therapeutics RLMD Stock Holding History

Ghost Tree Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500,000	Closed	-$18.5M	–	43
2022 Q3	$18.5M	Buy	+500,000	New	+$13.9M	5.2%	3

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ghost Tree Capital's RLMD Position: Q4 2022 in Review

Ghost Tree Capital sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 425,000 shares — an estimated $15.7M sold.

Ghost Tree Capital first reported a position in RLMD in Q3 2021 and held it in 5 quarters. The position peaked at $15.7M in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

Ghost Tree Capital reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
Ghost Tree Capital sold 425,000 Relmada Therapeutics shares in Q4 2022, an estimated $15.7M.
Ghost Tree Capital first reported a position in Relmada Therapeutics in Q3 2021 and held it in 5 quarters.
Ghost Tree Capital's Relmada Therapeutics position peaked at $15.7M in Q3 2022.
110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Ghost Tree Capital's 13F filing for Q4 2022, filed 14 Feb 2023.